Pharmaceuticals, Biotechnology & Life Sciences

Insider buying fuels Quantum Cyber’s pivot to healthcare cybersecurity—executives’ confidence signals a possible upside reversal.

IDEAYA insider Ruiz Briseno’s July 7, 2026 buy‑sell‑exercise move shows deep confidence in the company’s oncology pipeline and hints at future upside for shareholders.

Metzger’s dual buy‑sell move shows insider confidence in Syndax’s pipeline—locking in gains while keeping a large stake, a signal that may boost investor optimism.

CEO Fordyce Marshall sells 48,800 Vera Therapeutics shares at $42.78—steady 10b5‑1 plan amid a 52‑week high, boosting investor confidence.

Forum Markets insider sell signals a shift: Konstantin divests 3,702 shares amid bullish sentiment, hinting at portfolio rebalancing, not panic.

Silver Ronald’s Rule 10b5‑1 sale of 127,890 Ironwood shares is a planned exit, not a warning, and other insiders’ buying keeps confidence high.

Elanco CFO sells 15k shares: a liquidity move, not a confidence shift—insider buying stays strong, showing long‑term support for the company.

Curis insider Rubin Marc buys 6,800 shares at $5.29, signaling confidence in the company’s regenerative pipeline despite negative sentiment and upcoming option dilution.

Tonix CFO’s June 30 buy of 1,453 shares at $10.91 signals growing insider confidence amid a volatile market, hinting at future upside for investors.

Corcept Therapeutics insider sales show routine portfolio moves, not a shift in strategy – a sign of long‑term confidence for investors.